pamrevlumab

01/01/2020 - "Now in phase 3 development, pamrevlumab shows promise as a novel, safe, and effective treatment for idiopathic pulmonary fibrosis. "
08/01/2020 - "Pamrevlumab for the treatment of idiopathic pulmonary fibrosis."
01/01/2020 - "Pamrevlumab attenuated progression of idiopathic pulmonary fibrosis and was well tolerated. "
01/01/2020 - "The aim was to establish whether pamrevlumab could slow, stop, or reverse progression of idiopathic pulmonary fibrosis. "
01/01/2020 - "Pamrevlumab in idiopathic pulmonary fibrosis."

12/29/2015 - "These results warrant further studies into the therapeutic efficacy of FG-3019 in high-grade serous ovarian cancer. "

01/01/2020 - "These results are highly encouraging for use of FG-3019 for therapeutic treatment of persistent skeletal muscle fibrosis, such as those induced with chronic overuse."
01/01/2022 - "We also showed that pamrevlumab, a CTGF inhibitory antibody, partially attenuates fibrosis in the model. "
09/01/2020 - "An exciting paper recently published by Mary Barbe and the Popoff group has shown that FG-3019 reduces established muscle fibrosis (Barbe et al., FASEB J 34:6554-6569, 2020). "
01/01/2018 - "In this scenario, we show evidence that FG-3019 not only reduces fibrosis in skeletal muscle of hSOD1G93A mice, but also improves muscle and locomotor performance. "
02/01/2011 - "In keeping with this requirement for CTGF function in fibrosis, FG-3019 also reduced the renal Hyp:Pro response up to 20% after UUO (P < 0.05). "

12/02/2013 - "FG-3019 is effective in blocking extracellular matrix production in TM and LC cells, thus supporting a role for the use of anti-CTGF immunotherapy in the treatment of glaucoma."

07/23/2013 - "CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer."
03/10/2013 - "FG-3019 inhibits the connective tissue growth factor which is important in the biology of pancreatic cancer and was shown to be relatively safe in a phase I study (Abstract #213). "
03/10/2013 - "Further studying of FG-3019 and ASG-5ME will show the potential activity if any of these compounds in patients with pancreatic cancer."
01/01/2020 - "Drugs targeting the matricellular protein CCN2 (centralized communication network 2, formerly termed connective tissue growth factor), are in clinical development for cancers; for example, FG-3019, an antibody targeting CCN2 has recently entered Phase III trials for pancreatic cancer. "
01/01/2020 - "Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer."